Orforglipron (Foundayo)
The GLP-1 pill. FDA-approved in April 2026.
Grade A: Strong human proof
Big trials in people, and it worked.
The grade is for the use people talk about, not for every use. Filed under: Fat loss (GLP-1 family).
How it works
A daily pill that switches on the same GLP-1 receptor as semaglutide. It is a small molecule, not a peptide.
How it was given in studies
By mouth. It is a pill.
This is what the studies did. It is not a how-to. Source: Trial in 3,127 adults. NEJM, 2025; FDA label on DailyMed.
What studies saw
In a 72-week trial of 3,127 adults with obesity and no diabetes, weight fell 7.5% to 11.2% depending on the amount, against 2.1% on placebo.
The trade-off
Between 5% and 10% quit over side effects, mostly gut trouble, against 3% on placebo. The label carries a boxed warning about thyroid C-cell tumors.
When it showed up, in studies
7.5% to 11.2% weight loss at 72 weeks.
Sources
Put this grade on your site
Copy the line below. The badge links back to this page, so readers can check the sources. It grades the compound in studies. It does not rate any product or seller.
<a href="https://www.workedinrats.com/compounds/orforglipron-foundayo"><img src="https://www.workedinrats.com/badge/orforglipron-foundayo.svg" alt="Orforglipron (Foundayo): grade A, strong human proof. Worked in Rats" width="300" height="72"></a>
Keep going
We show what studies found. We never tell you what to take. Doses vary by study. Check the sources and talk to a doctor.